Clinical Implications of Early vs Late Development of Donor‐Specific Antibodies Among Lung Transplant Recipients: A Single‐Center Experience
Clinical Transplantation · 2026-05 · 40 (5)
DOI: 10.1111/ctr.70564 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Transplantation, online erschienen am 19.05.2026. Verfasst von Devika Sindu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Creighton University, Phoenix Regional Health Sciences Campus, Arizona, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Graft Rejection, Isoantibodies, Tissue Donors. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Lung transplant recipients (LTRs) can develop donor‐specific antibodies (DSAs), which are associated with antibody‐mediated rejection (AMR). LTRs at our center undergo regular DSA surveillance in the first year after lung transplant (LT), and LTRs that develop DSAs are treated, even in the absence of allograft dysfunction. We compared the clinical outcomes of LTRs without DSAs to those of LTRs that developed DSAs early after LT (< 3 months) or late after LT (3–12 months).
Methods
We retrospectively analyzed 428 LTRs transplanted at our center between February 2017 and June 2022. Of these, 94 were included in the no‐DSA group (mean fluorescence intensity [MFI] < 500) and 143 were included in the DSA groups (MFI ≥ 2000), with 131 in the early‐DSA group and 12 in the late‐DSA group. We compared the groups using Fisher's exact test, the median test, and Kaplan–Meier and Cox regression survival analyses.
Results
There was no statistically significant difference in 1‐ and 3‐year survival between the 3 groups; however, 3‐year survival in the late‐DSA group was 33%, with AMR as the cause of death in 2 of the 4 deceased LTRs. DSAs declined in the majority of patients in both the early and late groups. There were no significant differences in infectious complications between the groups ( p = 0.332).
Conclusion
LTRs with early DSAs and preemptive treatment have a good prognosis, with post‐LT overall survival and chronic lung allograft dysfunction (CLAD)‐free survival comparable to that of LTRs without DSAs. LTRs with late DSAs may have worse long‐term and CLAD‐free survival; however, larger studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Creighton University, Phoenix Regional Health Sciences Campus, Arizona, USA.
- Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Histocompatibility Laboratory, Vitalant, Phoenix, Arizona, USA.
Zitieren
APA
Sindu, D., Pham, C., Kohler, N., Bitar, G., Bowman, D., Grief, K., Walia, R., Franz, B. J., & Tokman, S. (2026). Clinical Implications of Early vs Late Development of Donor‐Specific Antibodies Among Lung Transplant Recipients: A Single‐Center Experience. Clinical Transplantation, 40(5). https://doi.org/10.1111/ctr.70564
Vancouver
Sindu D, Pham C, Kohler N, Bitar G, Bowman D, Grief K, et al. Clinical Implications of Early vs Late Development of Donor‐Specific Antibodies Among Lung Transplant Recipients: A Single‐Center Experience. Clinical Transplantation. 2026;40(5). doi:10.1111/ctr.70564
BibTeX
@article{Sindu2026,
author = {Sindu, Devika and Pham, Christine and Kohler, Nadia and Bitar, Gabriel and Bowman, David and Grief, Katherine and Walia, Rajat and Franz, Brian J and Tokman, Sofya},
title = {Clinical Implications of Early vs Late Development of Donor‐Specific Antibodies Among Lung Transplant Recipients: A Single‐Center Experience},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {5},
doi = {10.1111/ctr.70564}
}
EUVIMED